Sudeep Pharma Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Sudeep Pharma Ltd filed with BSE on 28 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Sudeep Pharma reported FY26 revenue growth of 27.9% to Rs 642.3 crore and EBITDA growth of 16.8% to Rs 221.9 crore, with EBITDA margin declining to 34.6% from 37.8% in FY25. Management attributed the margin decline to raw material cost pressures, higher operating expenses from team-building in Europe and North America, and lower utilization on newly introduced product lines. The company also discussed progress on its greenfield manufacturing expansion, the NSS acquisition integration, and the battery materials project at Dahej.
2 statements from this call are not shown because their supporting quotes could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: INR642.3 crores (FY26)
p. 7
“revenue from operations for FY26 grew by 27.9% on year-on-year basis to INR642.3 crores as compared to INR501.9 crores in FY25”
Ketan Vyas, page 7 of the filed PDF · View the filing
EBITDA: INR221.9 crores (FY26)
p. 7
“EBITDA for FY26 also grew by 16.8% to INR221.9 crores as against INR189.9 crores in FY25”
Ketan Vyas, page 7 of the filed PDF · View the filing
EBITDA margin: 34.6% (FY26)
p. 7
“EBITDA margin for the year stood at 34.6% as compared to 37.8% in FY25”
Ketan Vyas, page 7 of the filed PDF · View the filing
PAT: INR174.3 crores (FY26)
p. 7
“PAT for the year stood at INR174.3 crores as against INR138.7 crores in FY25”
Ketan Vyas, page 7 of the filed PDF · View the filing
Revenue from operations: INR182.3 crores (Q4 FY26)
p. 8
“revenue from operations for the quarter grew by 15.7% on Y-o-Y basis to INR182.3 crores in Q4 FY26 as compared to INR157.5 crores in Q4 FY25”
Ketan Vyas, page 8 of the filed PDF · View the filing
EBITDA: INR62.6 crores (Q4 FY26)
p. 8
“EBITDA for the quarter stood at INR62.6 crores as compared to INR58.8 crores in Q4 FY25”
Ketan Vyas, page 8 of the filed PDF · View the filing
EBITDA margin: 34.3% (Q4 FY26)
p. 8
“EBITDA margin for the quarter stood at 34.3%”
Ketan Vyas, page 8 of the filed PDF · View the filing
PAT: INR48.5 crores (Q4 FY26)
p. 8
“PAT for the quarter stood at INR48.5 crores as compared to INR44.2 crores in Q4 FY25”
Ketan Vyas, page 8 of the filed PDF · View the filing
Specialty ingredients revenue: INR280 crores (FY26)
p. 5
“Revenue for the vertical grew from INR172 crores to INR280 crores during the year”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Working capital days: 213 days (FY26)
p. 8
“our working capital days increased from 184 days to 213 days, which was mainly due to increase in inventory days”
Ketan Vyas, page 8 of the filed PDF · View the filing
Net debt: INR33.6 crores (as of 31st March 2026)
p. 8
“the company's net debt stood at INR33.6 crores with a net debt-to-equity ratio of 0.04x, reflecting a conservative and comfortable leverage position”
Ketan Vyas, page 8 of the filed PDF · View the filing
Gross capex: INR127 crores (FY26)
p. 12
“The gross capex spent during the year was INR127 crores, of which we spent on SAM land purchase of INR34 crores”
Ketan Vyas, page 12 of the filed PDF · View the filing
New customer approvals: 51 (FY26)
p. 6
“Compared to FY25, we received around 51 new customer approvals in FY26, which are expected to meaningfully contribute to the growth of the business in the coming financial year”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Battery materials customer purchase orders: approximately 700 metric tons (last month)
p. 7
“we have also started receiving initial commercial purchase orders, including approximately 700 metric tons over the last month alone”
Shanil Bhayani, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Battery materials Phase 1 commissioning — 25,000 metric tons per year · April 2027
stated firmly by Shanil Bhayani
p. 6
“which remains on track for commissioning of Phase 1 capacity of 25,000 metric tons per year by April 2027”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Net working capital days — 150 to 160 days · within this financial year
stated conditionally by Ketan Vyas
p. 8
“We are internally focused on managing our net working capital cycle and targeting to come around 150 to 160 days within this financial year”
Ketan Vyas, page 8 of the filed PDF · View the filing
Pharma food and nutrition EBITDA growth — 15% · FY27-FY28
stated as an aspiration by Shanil Bhayani
p. 10
“I think that would be -- that is I would say the expectation”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Battery materials sales volume — 2,500 metric ton · FY27
stated conditionally by Shanil Bhayani
p. 11
“That is a fair assumption, yes.”
Shanil Bhayani, page 11 of the filed PDF · View the filing
Battery materials capex — approximately INR600 crores · to reach 100,000 tons capacity
stated firmly by Shanil Bhayani
p. 12
“I had mentioned previously as well that to achieve our target of 100,000 tons, we are looking at a capex of approximately INR600 crores”
Shanil Bhayani, page 12 of the filed PDF · View the filing
Battery materials revenue potential — INR1,600 crores to INR1,800 crores · at 100,000 tons peak utilization
stated as an aspiration by Shanil Bhayani
p. 12
“we say between INR1,600 crores to INR1,800 crores is the potential for this at 100,000 tons utilization”
Shanil Bhayani, page 12 of the filed PDF · View the filing
Pharma food nutrition and specialty ingredients growth — FY27
stated as an aspiration by Shanil Bhayani
p. 12
“we expect actually pharma food nutrition to grow faster than it has grown in FY26 of 10%”
Shanil Bhayani, page 12 of the filed PDF · View the filing
Non-battery business revenue potential — INR1000 crores to INR1200 crores
stated as an aspiration by Shanil Bhayani
p. 13
“the business can scale to approximately INR1000 crores to INR1200 crores without any incremental capex in the existing product portfolio”
Shanil Bhayani, page 13 of the filed PDF · View the filing
Customer qualification timelines for greenfield facility — six to 12 months
stated conditionally by Shanil Bhayani
p. 6
“We expect customer qualification timelines to range between six to 12 months, depending on product categories and customer audit requirements”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said quantity/volume growth was actually north of 20%, but price increases for phosphoric acid were only passed on to customers from Q1 onward, so the benefit will show in upcoming quarters.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: Why has pharma food and nutrition segment growth of 10% been relatively muted compared to specialty ingredients, given raw material inflation pass-through?
p. 9
“the quantity volume growth is north of 20% in this category. What we are seeing is for phosphate specifically, the price increase we have only passed on to the customers in Q1”
Shanil Bhayani, page 9 of the filed PDF · View the filing
Management cited higher operational costs from running newer product categories like glycinate and gluconate at lower capacity, plus recruitment costs for the greenfield facility being expensed before revenue generation began.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: Why hasn't the reported 20% volume growth in pharma food and nutrition translated into EBITDA growth?
p. 10
“because we have not entirely started generating revenue, all of those, all those expenses of employees are also sitting in the pharma food nutrition vertical today”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Management attributed it to NSS not being part of last year's base, a one-time CSR expenditure, a premium paid for LPG due to shortage, and airfreight costs to a large customer due to production delays.
Answered by Shanil Bhayani
Asked by Sanjesh Jain: What explains the sharp sequential and year-on-year increase in other expenses this quarter?
p. 10
“there is an approximate, I think, INR3 crores CSR expenditure, which is in this quarter”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Management clarified the current capex figure includes land acquisition and infrastructure for future phases, and the total capex target for 100,000 tons capacity is approximately INR600 crores.
Answered by Shanil Bhayani
Asked by Nishita: What is the capex required for each incremental 25,000 metric tons of battery material capacity?
p. 12
“to achieve our target of 100,000 tons, we are looking at a capex of approximately INR600 crores”
Shanil Bhayani, page 12 of the filed PDF · View the filing
Management said the existing business can scale to Rs 1000-1200 crore without incremental capex once the greenfield facility is commissioned.
Answered by Shanil Bhayani
Asked by Nitin Gandhi: What is the maximum revenue potential of the business excluding battery materials?
p. 13
“the business can scale to approximately INR1000 crores to INR1200 crores without any incremental capex in the existing product portfolio”
Shanil Bhayani, page 13 of the filed PDF · View the filing
Management said the goal is not to compete with China on price but to offer a product competitive on performance, benefiting from China Plus One sourcing requirements.
Answered by Shanil Bhayani
Asked by Shreya Chatterjee: How competitive is Sudeep's battery materials business versus Chinese players?
p. 15
“the goal is not to compete with China. Our focus right from the beginning since we started this business has been to give a product which has, which is highly competitive from a performance perspective against the Chinese iron phosphate”
Shanil Bhayani, page 15 of the filed PDF · View the filing
Management said pharma food and nutrition utilization is 65-70% (excluding the new greenfield), and specialty ingredients utilization is 35-40%.
Answered by Shanil Bhayani
Asked by Shreya Chatterjee: What is the current capacity utilization across facilities excluding the battery materials business?
p. 15
“we are between 65% and 70% utilization on that vertical, which is why the greenfield. On specialty ingredients, we would be between 35% and 40% utilization”
Shanil Bhayani, page 15 of the filed PDF · View the filing
Risks flagged
Sharp increase in critical raw material prices, particularly phosphoric acid, due to higher sulfur costs globally
p. 5
“the business faced challenges during the year due to sharp increase in critical raw material prices, particularly phosphoric acid, arising from higher sulfur costs globally”
Shanil Bhayani, page 5 of the filed PDF · View the filing
Delay in greenfield facility commissioning due to LPG and energy supply disruptions
p. 6
“During the year, the project experienced some delay in commissioning, primarily due to shortages and disruptions in LPG and energy supplies”
Shanil Bhayani, page 6 of the filed PDF · View the filing
Volatile operating environment including geopolitical uncertainty, raw material inflation, logistic disruption and energy supply challenges
p. 4
“These investments were undertaken despite a highly volatile operating environment characterized by geopolitical uncertainty, raw material inflation, logistic disruption, energy supply challenges, and evolving global trade dynamics”
Shanil Bhayani, page 4 of the filed PDF · View the filing
LPG shortage in March forcing premium payments and higher power and fuel costs
p. 10
“in March, we had a significant shortage of LPG and our specialty ingredients vertical runs on this. So we basically paid a significant premium to CQ and we built a larger inventory”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Production delays requiring costly airlifting of material to largest customer
p. 10
“because of certain production delays in March because of lower capacity, we had to airlift material to our largest customer”
Shanil Bhayani, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.